04-4-7J-012, awarded by the Defense Threat Reduction Agency. This invention was made with Government support under Project No. STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT 15, 2009, the disclosures of all of which are hereby incorporated by reference in their entireties for all purposes. 28, 2014, which application is a continuation of Ser. The present application is a continuation of U.S. The composition of claim 1, wherein the first interfering RNA further comprises a sense strand comprising one of the sense strand sequences set forth in Table 1. The composition of claim 1, wherein the first interfering RNA comprises an antisense strand comprising nucleotides 1-19 of one of the antisense strand sequences set forth in Table 2.Ģ0. The composition of claim 1, wherein the first interfering RNA comprises an antisense strand comprising at least 15 contiguous nucleotides of one of the antisense strand sequences set forth in Table 2.ġ9. The composition of claim 1, wherein the first interfering RNA comprises an antisense strand comprising one of the antisense strand sequences set forth in Table 2.ġ8. The composition of claim 15, wherein the antisense strand comprises a 5′-TT-3′ overhang and the sense strand comprises a 5′-TT-3′ overhang.ġ7. The composition of claim 1, wherein the first interfering RNA further comprises a sense strand comprising the following sequence: 5′-GUACGAAGCUGUAUAUAAA-3′.ġ6. The composition of claim 13, wherein the 2′OMe nucleotides comprise at least one, two, three, or four 2′OMe-guanosine nucleotides, 2′OMe-uridine nucleotides, or mixtures thereof.ġ5. The composition of claim 12, wherein the modified nucleotides comprise 2′-O-methyl (2′OMe) nucleotides.ġ4. The composition of claim 11, wherein one or more of the nucleotides in the 3′ overhang of one or both strands comprise modified nucleotides.ġ3. The composition of claim 3, wherein the siRNA comprises a 3′ overhang in one or both strands of the siRNA.ġ2. The composition of claim 7, wherein less than about 50% of the nucleotides in the double-stranded region comprise modified nucleotides.ġ1. The composition of claim 8, wherein the 2′OMe nucleotides comprise at least one, two, three, four, five, six, seven, eight, nine, ten, or eleven 2′OMe-guanosine nucleotides, 2′OMe-uridine nucleotides, or mixtures thereof.ġ0. The composition of claim 7, wherein the modified nucleotides comprise 2′-O-methyl (2′OMe) nucleotides.ĩ. The composition of claim 6, wherein one or more of the nucleotides in the double-stranded region of the siRNA comprise modified nucleotides.Ĩ. The composition of claim 3, wherein the siRNA comprises a double-stranded region of about 19 to about 25 nucleotides in length.ħ. The composition of claim 1, wherein the third interfering RNA comprises an siRNA.Ħ. The composition of claim 1, wherein the second interfering RNA comprises an siRNA.ĥ. The composition of claim 1, wherein the first interfering RNA comprises an siRNA.Ĥ. The composition of claim 1, wherein the composition comprises the first and second interfering RNA, the first and third interfering RNA, the second and third interfering RNA, or the first, second, and third interfering RNA.ģ. A composition comprising at least two interfering RNA selected from the group consisting of: (a) a first interfering RNA that silences Ebola virus L-pol expression, wherein the first interfering RNA comprises an antisense strand comprising the following sequence: 5′-UUUAUAUACAGCUUCGUAC-3′ (b) a second interfering RNA that silences Ebola virus VP24 expression, wherein the second interfering RNA comprises an antisense strand comprising the following sequence: 5′-UUUGCAUUCGUGUCGAGGA-3′ and (c) a third interfering RNA that silences Ebola virus VP35 expression, wherein the third interfering RNA comprises an antisense strand comprising the following sequence: 5′-AUGAUGUCCAAUGAGUUGC-3′.Ģ. Radical reaction inhibitors, method for inhibition of radical reactions, and use thereofġ. Treatment of diabetes with thiazolidinedione and sulphonylurea Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS Novel maxi-k channel blockers, methods of use and process for making the sameĮXTENDED RELEASE PHARMACEUTICAL DOSAGE FORMS OF CARBIDOPA AND LEVODOPA AND PROCESS OF PREPARATION THEREOFĮNANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF Transglutaminase Variants with Improved Specificity
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |